Blood tests being studied to help detect ovarian cancer
Compares investigational blood tests in women with and without ovarian cancer.
Plain-language title generated from the registry record
Registry title: Innovative Ovarian Cancer Biomarker Assays
Key facts
- Where
- Athens, GreeceSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 35 or older with newly diagnosed epithelial ovarian cancer, and women of the same age with no cancer history as comparison. It tests blood-based ovarian cancer tests.
- Age
- 35 years or older
- Sex
- Women, trans men and non-binary people with female reproductive organs
- Disease stage
- Cancer patients: epithelial ovarian cancer confirmed by biopsy before any surgery or treatment, with a suspicious mass near the ovary on imaging, and surgery or biopsy scheduled. Comparison group: no cancer history.
- Earlier treatment
- Patients must not have had surgery or treatment for the ovarian cancer before joining. Nobody can have had treatment for any cancer before.
Main reasons for not taking part
- Earlier cancer or treatment for cancer
- Either ovary removed before, for any reason
- Pregnant or breastfeeding
- Any condition the investigator thinks could stop the person from taking part or following the study
Read by machine on 12 November 2026.
Where in Greece
- Dept of Clinical Therapeutics, Alexandra HospitalAthens, GreeceContact: Michael LiontosTaking people
- National Centre for Scientific Research DemokritosAthens, GreeceContact: Florentia FostiraTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- National and Kapodistrian University of Athens
- Trial code
- NCT07693894
- Record updated
- 1 October 2026
- Original description
Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes.Read full original descriptionShow less
Multi-site, Multi-country Evaluation of Innovative Ovarian Cancer Biomarker Assays. (DISARM Clinical Study B-CSB)
Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes.
Recent research has focused on the development of blood-based tests, sometimes referred to as liquid biopsy tests, which aim to look for changes in the blood that could be linked to cancer. These tests are still under investigation and are not part of routine clinical care.
The purpose of this study is to evaluate several blood-based ovarian cancer tests. This will be done by comparing test results from people who have ovarian cancer with results from people who do not have cancer.
The study will also collect information from standard blood tests and genetic analyses to better understand how these results relate to ovarian cancer.
This study is for research purposes only. The blood-based tests being evaluated are investigational and are not used to make medical decisions or diagnoses for women taking part in the study.
Inclusion: EOC patients; Women, trans men and non-binary people with female reproductive organs; Aged ≥35 years*; Pathologically diagnosed, by biopsy, with EOC prior to surgical intervention or treatment; Presenting with adnexal mass suspicious of OC on imaging and scheduled for surgical resection or biopsy (and subsequent confirmation of EOC); Able to give informed consent; Healthy controls; Women, trans men and non-binary people with female reproductive organs; Aged ≥35 years; No cancer history; Able to give informed consent.
Exclusion: Prior history and any treatment for malignancy; Prior removal of either ovary for any reason; Any condition or circumstance that, in the opinion of the investigator, could interfere with the participant's ability to participate or comply with study requirements; Pregnant or lactating.